Pharmacological degradation of ATR induces antiproliferative DNA replication stress in leukemic cells.
ATR
DNA replication stress
PROTAC
cereblon
leukemia
Journal
Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230
Informations de publication
Date de publication:
22 Mar 2024
22 Mar 2024
Historique:
revised:
05
02
2024
received:
24
01
2024
accepted:
12
03
2024
medline:
23
3
2024
pubmed:
23
3
2024
entrez:
23
3
2024
Statut:
aheadofprint
Résumé
Mammalian cells replicate ~ 3 × 10
Identifiants
pubmed: 38520049
doi: 10.1002/1878-0261.13638
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : SFB1361
Organisme : Deutsche Forschungsgemeinschaft
ID : SFB1292TP21N
Organisme : Deutsche Forschungsgemeinschaft
ID : KR2291
Organisme : Deutsche Forschungsgemeinschaft
ID : SI868/22-1
Organisme : German Academic Exchange service
Organisme : Walter Schulz-Stiftung
Organisme : Brigitte und Dr. Konstanze Wegener-Stiftung
Informations de copyright
© 2024 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
Menolfi D, Zha S. ATM, ATR and DNA‐PKcs kinases‐the lessons from the mouse models: inhibition not equal deletion. Cell Biosci. 2020;10(8):8.
da Costa A, Chowdhury D, Shapiro GI, D'Andrea AD, Konstantinopoulos PA. Targeting replication stress in cancer therapy. Nat Rev Drug Discov. 2023;22(1):38–58.
Mahajan K, Mahajan NP. Cross talk of tyrosine kinases with the DNA damage signaling pathways. Nucleic Acids Res. 2015;43(22):10588–10601.
Saldanha J, Rageul J, Patel JA, Kim H. The adaptive mechanisms and checkpoint responses to a stressed DNA replication fork. Int J Mol Sci. 2023;24(13):10488.
Lecona E, Fernandez‐Capetillo O. Targeting ATR in cancer. Nat Rev Cancer. 2018;18(9):586–595.
Mustafa AM, Krämer OH. Pharmacological modulation of the crosstalk between aberrant Janus kinase signaling and epigenetic modifiers of the histone deacetylase family to treat cancer. Pharmacol Rev. 2023;75(1):35–61.
Chirnomas D, Hornberger KR, Crews CM. Protein degraders enter the clinic – a new approach to cancer therapy. Nat Rev Clin Oncol. 2023;20:265–278.
Brand M, Jiang B, Bauer S, Donovan KA, Liang Y, Wang ES, et al. Homolog‐selective degradation as a strategy to probe the function of CDK6 in AML. Cell Chem Biol. 2019;26(2):300–306.e9.
Göder A, Emmerich C, Nikolova T, Kiweler N, Schreiber M, Kühl T, et al. HDAC1 and HDAC2 integrate checkpoint kinase phosphorylation and cell fate through the phosphatase‐2A subunit PR130. Nat Commun. 2018;9(1):764.
Beyer M, Henninger SJ, Haehnel PS, Mustafa AM, Gurdal E, Schubert B, et al. Identification of a highly efficient dual type I/II FMS‐like tyrosine kinase inhibitor that disrupts the growth of leukemic cells. Cell Chem Biol. 2022;29(3):398–411.e4.
Fischer MA, Mustafa AM, Hausmann K, Ashry R, Kansy AG, Liebl MC, et al. Novel hydroxamic acid derivative induces apoptosis and constrains autophagy in leukemic cells. J Adv Res. 2023;17(7):S2090‐1232.
Alfayomy AM, Ashry R, Kansy AG, Erdmann F, Schmidt M, Krämer OH, et al. Design, synthesis, and biological characterization of proteolysis targeting chimera (PROTACs) for the Ataxia telangiectasia and RAD3‐related (ATR) kinase. Eur J Med Chem. 2024;5(3):267.
Nguyen TM, Deb A, Praveen Kokkonda P, Vedagopuram Sreekanth V, Tiwari PK, Shoba V, et al. Proteolysis targeting chimeras with reduced off‐targets. Nat Chem. 2024;16(2):218–228.
Toledo L, Neelsen KJ, Lukas J. Replication catastrophe: when a checkpoint fails because of exhaustion. Mol Cell. 2017;66(6):735–749.
Rogakou EP, Nieves‐Neira W, Boon C, Pommier Y, Bonner WM. Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J Biol Chem. 2000;275(13):9390–9395.